Macro

Global pharmaceutical sales are projected to exceed $2 trillion by 2032, driven by obesity and inflammatory drugs, according to Evaluate's World Preview 2026 report. Eli Lilly's tirzepatide (Mounjaro/Zepbound) is forecast to generate over $70 billion that year, making it the biggest drug ever, while AbbVie's Skyrizi is expected to be the second top-seller at $33 billion. The report highlights a resurgence in M&A, with Chinese assets accounting for over two-thirds of 2026 deal value. However, challenges include U.S. drug pricing pressures, a patent cliff risking $500 billion in sales, and increasing competition in popular indications.

Artificial intelligence is transforming drug discovery by cutting development timelines from years to weeks, addressing a pipeline where 90% of candidates fail. Peptide-based medicines, built from amino acids, are especially suited for AI-driven optimization, enabling rapid analysis of molecular combinations. Eli Lilly's tirzepatide franchise generated $36.5 billion in 2025 revenue (up 215%), and Novo Nordisk's GLP-1 portfolio reached $34.6 billion. Schrodinger's simulation software, used by 18 of the top 20 pharma companies, posted 12% revenue growth in Q1 2026. AI is also overcoming manufacturing and delivery challenges, positioning peptide drugs as a major biotech growth opportunity.

Eli Lilly and Novo Nordisk are leading the S&P 500 healthcare sector, with a focus on metabolic conditions such as diabetes and obesity. A key development is the emergence of oral obesity therapies, which offer a pill-based alternative to traditional injections, potentially expanding patient access. Both companies' large-scale operations and market capitalizations make them major constituents of the index.

IDEXX Laboratories (IDXX) has underperformed the Nasdaq Composite, with shares down 17.1% year-to-date versus NASX's 11.6% gain, due to softening demand in the companion animal market and FX headwinds. Despite outperforming rival Zoetis (ZTS), the stock trades below key moving averages, reflecting investor caution. Analysts maintain a 'Moderate Buy' consensus, citing a 30.4% upside potential.

President Trump announced via social media a plan to impose 100% tariffs on imported generic drugs starting in August 2028, escalating to 200% after one year, to force manufacturers to move production to the U.S. The proposal targets a nearly $500 billion global industry where generics account for 90% of U.S. prescriptions; India supplies over 50% of these drugs, and China provides most active pharmaceutical ingredients. Industry experts and representatives expressed skepticism, noting generic manufacturers operate on single-digit margins, making the tariffs effectively a "market-exit notice." Building domestic manufacturing takes at least four to five years, according to India's Pharmexcil chairman, suggesting the two-year tariff-free period may be insufficient. The Association for Accessible Medicines called for broader policy changes. Companies with existing U.S. production, like Amphastar and Hikma, are better positioned, while Teva and Viatris face greater exposure. It remains unclear if tariffs apply to finished drugs only or also to those using imported ingredients. New reporting highlights that generic drugmakers, unlike patented pharma giants like Johnson & Johnson and Eli Lilly, operate on thin margins due to price wars—prices can fall 70% in two years after patent expiry—making reshoring less viable. Erez Israeli, CEO of Dr. Reddy's, stated tariffs would force price increases in the U.S., and the Global Trade Research Initiative noted many Indian generics would remain cost-competitive even after 100% tariffs, with costs likely passed to patients, insurers, and providers.

Eli Lilly reported Q1 2026 revenue of $19.80 billion, up 55.5% year-over-year, beating consensus estimates, and raised full-year guidance by $2 billion. The FDA cleared Foundayo, the first any-time-of-day oral GLP-1 drug, which drove 80% new-to-class prescriptions in early launch data. Mounjaro revenue surged 125% to $8.66 billion, and Zepbound rose 80% to $4.16 billion. The company also completed a $6.3 billion Centessa acquisition and a $6.5 billion manufacturing plant investment. However, realized prices fell 13% amid volume gains, and Novo Nordisk filed a false-advertising lawsuit. 24/7 Wall St. set a $1,365.51 price target with a buy rating, citing Foundayo's potential to expand the oral obesity market globally.

Indian stock markets suffered their steepest fall in 10 sessions on Wednesday, extending losses to a third consecutive day. The BSE Sensex dropped 715.06 points (0.92%) to 76,755.05, while the Nifty50 fell 191.45 points (0.79%) to 23,996.25, erasing approximately Rs 4.2-4.25 lakh crore in investor wealth. The selloff was driven by escalating US-Iran tensions—with the 11th consecutive night of US strikes targeting Iranian military infrastructure—and a sharp spike in crude oil prices, with Brent surging 3.5% to $94.20 per barrel and WTI climbing 3.8% to $87.56, raising concerns about supply disruptions through the Strait of Hormuz. Additional pressure came from US President Donald Trump's phased tariff plan on imported generic medicines, proposing zero tariffs for two years starting August 1, 2026, followed by 100% for one year and then 200%, hitting India's dominant pharma export sector. The Indian rupee weakened to 96.36 per dollar, while US Treasury yields rose. Broad-based selling hit banking, IT, auto, and pharma stocks, with foreign institutional investors likely net sellers. Analysts expect near-term volatility to persist, hinging on global crude prices and geopolitical developments.

Eli Lilly shares have surged 13.4% this year and 58% over 52 weeks, while Novo Nordisk has fallen 5% over the same period and 62% since July 2024, driven by diverging fortunes in the GLP-1 drug market. The global obesity drug market reached $66 billion in 2025 and is projected to hit $120 billion by 2030. Lilly now holds a 60% share of prescription obesity revenue, largely due to its Zepbound drug, while the two companies collectively control 87% of the market. Novo Nordisk has introduced Wegovy in pill form this spring, boosting its forecasts, but its shares remain under pressure.

On July 29, Piper Sandler chief market technician Craig Johnson declared the Magnificent 7 trade over, citing a market rotation into Health Care and Financials. He noted the Invesco QQQ Trust fell 4.72% in the past week, while the Health Care Select Sector SPDR Fund rose 4.37% and the Financial Select Sector SPDR Fund gained 7.52% over the past month. Johnson highlighted Microsoft's short interest at a decade-high percentage of float since 2015, despite strong Q3 FY2026 earnings, and NVIDIA's 85.2% revenue growth failing to boost its stock. Piper Sandler has cut tech weightings since February, advocating profit-taking. A bullish counterpoint from Sylvia Jablonski cited sustained AI demand, while economist Veronica Clark warned of economic exposure to sentiment shifts. The debate centers on whether this is a healthy correction or a lasting leadership change.

The July Personal Consumption Expenditures (PCE) price index rose 3.7% year over year, topping economists' 3.6% estimate and remaining well above the Federal Reserve's 2% target, while core PCE held at 3.3% and monthly headline and core PCE both increased 0.2%. This hot inflation reading pushed Treasury yields higher and dampened rate-cut hopes, prompting investors to rotate into defensive ETFs. Funds like the Consumer Staples Select Sector SPDR ETF (XLP), Health Care Select Sector SPDR ETF (XLV), Utilities Select Sector SPDR ETF (XLU), Vanguard Health Care ETF (VHT), and Invesco S&P 500 Low Volatility ETF (SPLV) offer exposure to less cyclical sectors such as staples, healthcare, and utilities, or lower-volatility stocks, providing a steadier path amid persistent inflation and rising rates. XLP's top holdings include Walmart, Costco, and Procter & Gamble, while XLU's capital-intensive nature keeps it sensitive to interest rates, with State Street holding a neutral view on utilities. SPLV selects the 100 least volatile S&P 500 stocks to reduce portfolio volatility.

The Federal Reserve may raise interest rates in October, with CME Group's FedWatch tool showing a 57.7% probability of a hike at the late-October FOMC meeting, following a 44.1% chance in September. Despite the potential for rising rates to hurt many stocks, three are recommended as buys: UnitedHealth Group, which has seen a 20% year-to-date gain and a 54% earnings jump in Q2 2026; JPMorgan Chase, which benefits from higher net interest income, reporting $25.6 billion in Q2; and Chevron, which gains from elevated fuel prices tied to the Iran war and resurging inflation, with shares up over 20% in 2026.

Baron Health Care Fund's Q2 2026 investor letter highlighted Eli Lilly as a top performer in the obesity drug market, which it projects could exceed $150 billion. Eli Lilly's GLP-1 therapies, including the new daily oral Foundayo, gained coverage from all three major pharmacy benefit managers, reversing prior concerns about a price war with Novo Nordisk. Phase 3 data for retatrutide showed weight loss in the high-20% range at higher doses, while eloralintide demonstrated Zepbound-like efficacy. Eli Lilly closed at $1,121.36 per share on August 3, 2026, with a market cap of $1.06 trillion, up 46.40% over 52 weeks.

Eli Lilly and Novo Nordisk reported starkly contrasting Q2 2026 results in the weight-loss drug market. Lilly posted 48% revenue growth, driven by $14.9 billion in combined Mounjaro and Zepbound sales, capturing roughly 60% of U.S. obesity prescriptions and raising full-year guidance to $85–$87 billion. Novo Nordisk saw adjusted sales rise 7% but gross margins fall to 78.2%, took a DKK 6.3 billion impairment, cut nearly 12,000 jobs, and announced a 50% list price cut for Wegovy effective January 2027. Lilly’s retatrutide met Phase 3 endpoints with weight loss approaching bariatric surgery levels, targeting a U.S. BLA submission in Q1 2027, while Novo’s Wegovy pill reached over 5 million prescriptions, capturing 90% of the oral obesity market. Lilly’s stock rose 77.98% over one year, while Novo trades at an 11 PE with a 3.84% dividend yield.

On August 19, 2026, Moderna and Merck announced that their personalized mRNA cancer vaccine, intismeran (mRNA-4157), combined with Keytruda, succeeded in the Phase 3 INTerpath-001 trial for high-risk adjuvant melanoma, marking the first positive late-stage result for an mRNA cancer therapy and a potential first approved medicine whose genetic instructions are determined by a computer algorithm. The double-blind, placebo-controlled study enrolled over 1,100 patients (1,137 total) with stage IIB–IV melanoma whose tumors were surgically removed, randomized 2-1 to receive the combination or Keytruda alone for about a year. An interim analysis showed the combination significantly extended recurrence-free survival and distant metastasis-free survival, meeting both primary and key secondary endpoints, with the data strong enough to stop the trial early. The five-year Phase 2b data, presented at ASCO 2026, had already shown a 49% reduction in recurrence or death risk and a 59% reduction in distant metastasis or death risk compared to Keytruda alone. The results are considered a landmark: Dr. Julie Gralow, chief medical officer of ASCO, described them as a monumental step forward in validating mRNA technology as a cancer treatment, while Moderna CEO Stéphane Bancel told CNN the results were comparable in significance to the company's November 2020 COVID-19 vaccine data, calling it a new chapter in cancer care. The news sent Moderna shares up 177% to close at $174.38, adding about $45 billion to its market value, while Merck shares rose 12% to a record high of $152.20. The health-care sector rallied, with the Health Care index rising more than 4% in the five trading days leading up to August 21. BioNTech jumped 20.3% to $111.55, and Eli Lilly rose 4.5%, pushing its market cap above $1.2 trillion, the first pharmaceutical company to cross that level. The Nasdaq Biotechnology Index climbed 4.4% to a record closing high. Short sellers faced paper losses of roughly $4.8 billion, as Moderna is one of the most shorted large-cap stocks with short interest at 13.5%. The results surprised even insiders: at a March 2023 leadership meeting, Bancel asked executives who expected the treatment to succeed to stand; none did, including Bancel and President Stephen Hoge, who later told STAT, 'None of us believed it.' RBC Capital Markets analysts wrote that the readout was 'surprisingly positive as we were expecting a year-end readout,' adding that 'the strength of the underlying data must have been compelling to trigger significance at the interim analysis, meaningfully exceeding investor expectations.' The companies have not yet published findings in a peer-reviewed setting but plan to present full data at an upcoming medical conference, possibly ESMO in Madrid from October 23-27, and share results with regulators. Overall survival data are pending and will be evaluated as the study continues. Dr. Ezekiel Emanuel called the results 'a home run, maybe even a grand slam,' while eToro analyst Lale Akoner advised measured expectations, noting manufacturing personalized vaccines at scale could be expensive and complex. The vaccine targets up to 34 unique cancer mutations per patient, built from the tumor's mutational fingerprint. Jefferies’ Tycho Peterson called the update an important proof point for mRNA modality beyond COVID. Bank of America’s Alec Stranahan viewed it as a watershed moment, allowing Moderna to diversify away from infectious disease. Citigroup’s Geoff Meacham noted meeting DMFS with no new safety signals is encouraging but said validation depends on full data and evidence across tumor types. JPMorgan’s Jessica Fye saw the launch as key to profitability but noted success in adjuvant melanoma was already priced in at an 85% probability of success, with read-across to other indications critical for further value. RBC’s Trung Huynh estimated the treatment could be worth up to $2.5 billion and expected a significant 'halo effect' across the robust cancer program. Merck generated $31.68 billion from Keytruda and Keytruda Qlex in 2025, nearly half of the company's sales, and the combination could help extend the franchise beyond Keytruda's primary compound patent expiration in December 2028, though biosimilars have already entered some smaller international markets. William Blair analysts wrote that positive results from INTerpath-001 add positive read-through for ongoing studies of intismeran in other cancer types, specifically flagging a potentially registrational Phase 2 study in adjuvant renal cell carcinoma with data expected by year-end. The companies are also studying intismeran combinations in non-small cell lung, bladder, pancreatic, and stomach cancers. The future of mRNA research faces uncertainty under the Trump administration, with Health Secretary Robert F. Kennedy Jr. criticizing the technology and cutting $500 million in contracts last year. The combined therapy has a huge addressable market: by year-end, the US is expected to register 112,000 new melanoma cases with 8,500 deaths, and globally 330,000 cases were diagnosed in 2022. Hedge funds were bullish on Moderna even before the results, with increased institutional positions and committed capital. An estimated 2.1 million new cancer cases will be diagnosed in the United States this year and an estimated 626,000 will die, according to the American Cancer Society. Personalized cancer vaccines based on the same mRNA technology that brought COVID-19 vaccines to market in record time are showing promising results against certain cancers, despite conflicting signals from U.S. officials about mRNA's technology, safety and potential. 'Personalized cancer vaccines are individualized therapies that train a patient's immune system to recognize and kill cancer cells,' said Dr. Ryan Sullivan, Director of Cutaneous Medical Oncology at Mass General Brigham Cancer Institute. 'These are very promising results that give hope to patients with melanoma and to the entire field of cancer vaccination.' Researchers have been developing vaccines for melanoma, lung, breast, pancreatic, prostate, brain and other cancers. The vaccines are designed to help the immune system recognize tumor-specific markers and attack cancer cells while sparing healthy tissue. One study has kept melanoma at bay for five years. Despite a $500 million reduction in federal support for mRNA technology last year, researchers are reporting encouraging results from personalized cancer vaccines that may reduce the risk of cancer returning by 50%. There have been three notable mRNA cancer vaccine studies and clinical trials: melanoma (skin cancer), which showed a reduced risk of cancer recurrence and spread; pancreatic cancer, which generated cancer-fighting T cells linked to extended remission; and brain cancer, which showed early signs of activating immune defenses against aggressive tumors. Researchers have conducted more than 120 clinical trials of mRNA cancer vaccines since the early 2000s, investigating their potential against numerous cancer types. Cancer vaccine research is advancing rapidly, according to the American Cancer Society. Scientists are developing better methods to identify tumor targets, including those based on mRNA technology, that can help the immune system more effectively recognize and destroy cancer cells. Researchers are also exploring combinations of cancer vaccines and other treatments, such as checkpoint inhibitor immunotherapy, to strengthen the body's anti-cancer response. According to the Cancer Research Institute, 'As exciting as these findings are, there is still much to learn.' Developing and bringing an mRNA cancer vaccine to the public can take 10 to 15 years.

The US-China trade truce on critical minerals, agreed on October 30, 2025, in Busan, South Korea, and extended by 60 days to January 10, 2027, faces expiration, risking global supply chain shortages. China suspended export restrictions on at least 22 minerals and materials, including rare earth elements, which if fully enforced, could disrupt up to $6.5 trillion per year of downstream production outside China, per the International Energy Agency. The deal also suspended the BIS Entity List 50% Affiliates Rule. If not extended, industries like medical devices, aerospace, military, automotive, and electronics would face severe shortages, as alternative supplies outside China are inadequate—only 25% of battery demand could be met. Companies would struggle with China's unreliable export license process, risking long delays and overwhelming the system.

China has unveiled a 2030 plan to become a global leader in biomedical innovation, targeting 25% of the world's first-in-class drugs and 3.5 trillion yuan ($520bn) in annual industry revenue. The initiative, announced via a joint ministerial notice, outlines 25 priority tasks including ramping up R&D, using AI and quantum computing in drug discovery, and building pharma ecosystems. It aims for 50 companies with over $1.5bn in annual revenue and at least five Chinese drugs achieving $1bn in global sales. Emphasis is on next-generation therapies like ADCs, cell and gene therapies, and mRNA vaccines, alongside modernizing traditional Chinese medicine. Citi analysts described the plan as a shift from scale-driven to innovation-driven growth.

Dr. Fanta Aw, executive director of NAFSA, warns that U.S. immigration policy is driving away international life sciences talent, risking the country's leadership in biotech innovation. A proposed four-year cap on student visas, blocked by a federal judge on September 14, would have forced all international PhD students to seek extensions, as no U.S. PhD program is four years. Aw argues the cap is a 'solution in search of a problem,' given the existing SEVIS tracking system. Broader policies—including travel bans, social media screening, and visa revocations for minor infractions—have created a climate of fear. International students comprise nearly 60% of U.S. life sciences postdocs, but page views for U.S. PhD programs have dropped 40% or more, and STEM PhD enrollments fell by 47,000 in 2025-2026. Meanwhile, countries like Germany and South Korea are actively recruiting these scientists. Aw warns that once trust is lost, it will be difficult to rebuild, and the next major biotech breakthrough may occur outside the U.S.

Eli Lilly is strengthening its lead in the GLP-1 weight loss drug market, now holding 60% of the U.S. market versus Novo Nordisk's 38%. A key recent development is Medicare's coverage of obesity drugs since July, which CEO Dave Ricks says has brought 700,000 new seniors into treatment, with Lilly capturing about 70% of those prescriptions—potentially adding roughly 490,000 patients. Lilly's injectable tirzepatide (Zepbound/Mounjaro) generated $9.09 billion and $18.61 billion in the first half of 2026, respectively, up 60% and 106% year over year, together representing 65% of Lilly's total revenue. Its first oral weight loss drug, Foundayo, has been chosen by over 30% of new oral GLP-1 patients since launch, though Novo's earlier-launched oral pill still has more total prescriptions. Foundayo's clinical data in adults 65 and older showed up to 13% mean weight reduction at 72 weeks. The Medicare 'Bridge' program offers a $50 monthly co-pay and runs through December 2027, while Lilly is expanding manufacturing capacity to meet demand. The data suggests insurance expansion is drawing new patients into the market, not just shifting existing ones.

Eli Lilly secured FDA approvals for Olumiant in adolescents with severe alopecia areata and once-weekly insulin Onswik for adults with type 2 diabetes, broadening its product mix across immunology and diabetes care. The approvals come as Medicare expands coverage of GLP-1 therapies, boosting demand for Lilly's obesity and diabetes drugs like Mounjaro and Zepbound. The Onswik approval reinforces Lilly's diabetes footprint by offering a weekly insulin option that can be prescribed alongside incretin therapies. Analysts forecast revenues of $118.6 billion and earnings of $49.8 billion by 2029, with some bullish models projecting up to $137.7 billion in revenue. Key risks include pricing pressure on GLP-1s and slow adoption of new products.

A global helium shortage has worsened seven months after Iranian strikes on Qatar's Ras Laffan facility and the closure of the Strait of Hormuz, which trapped one-third of global supply. Qatar, the second-largest producer after the U.S., may take three years to fully restore operations. Helium is critical for semiconductors, MRI machines, weapons production, and scientific research, with no substitute. Spot prices have tripled since the war began. U.S. exports are up 70%, but cannot offset the shortage indefinitely. Suppliers have imposed rationing, forcing labs and manufacturers to cut usage by 50%. The Pentagon's demand for weapons further strains supply, and the conflict's duration remains uncertain.

China proposed new export bans on 14 technologies in AI, biotechnology, and solar power, with additional restrictions on 26 more. The draft, issued Friday by the Ministry of Commerce and Ministry of Science and Technology, targets advanced AI models, agents, computing clusters, certain cell and gene therapy platforms, and solar cell module production tech. Public-domain technologies like open-source systems and published academic work are exempt.

Markets are rotating from technology and communications services into defensive sectors like healthcare, utilities and consumer staples, while the S&P 500 remains broadly stable. Global oil prices have spiked back toward 2026 highs. The probability of a Federal Reserve rate hike at its October meeting has dropped from about 70% in September to under 10%, while odds of a Canadian rate hike have risen above 80%. Credit default swap prices on U.S. hyperscaler debt have increased this year, and the share of leveraged ETFs holding a single stock has climbed 12 percentage points since 2024 to 28% in 2026.

Health insurance premiums for family plans jumped 9% in 2026, averaging $7,471, according to KFF's survey, driven by rising healthcare costs and pushing small businesses to drop coverage. Concurrently, the uninsured rate among working-age adults rose to 11.2% in 2026, up from 8.9% in 2024, per the Commonwealth Fund, due to expired ACA premium tax credits and rolled-back Medicaid protections. Half of uninsured adults forwent needed care due to cost. Experts warn that further Medicaid cuts and ACA restrictions in 2027 will worsen access.

Bank of America analysts have identified a 'bubble-like' pattern in the stock market reminiscent of the late 1990s dot-com era, driven by a rally in defensive sectors such as healthcare, materials, and consumer staples, which have risen 15%, 14%, and 12% respectively in 2026. Energy, boosted by the Iran war and surging oil prices, is up 52%. The bank's Bubble Risk Indicator has moved toward risky levels, echoing pre-crash dynamics seen in January 2000 and before the pandemic crash. Analysts note falling Treasury yields amid an AI trade sell-off, suggesting expectations of economic weakness. Despite warnings, they anticipate a 'clearing event for risk' that could lead to a bullish shift, as US stocks face volatility over Big Tech's AI spending and potential slowdowns.